Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.39 |
| ▸ | NRP1 | O14786 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8806276 | 0.83 | ADORA3 (0.42) | RAB9AMEN1KMT2ANPC1NR2F2 | |
| SCHEMBL8805373 | 0.83 | USP2 (0.40) | RAB9AMEN1KMT2ANPC1NR2F2 | |
| SCHEMBL8807136 | 0.83 | NRP1 (0.41) | RAB9AMEN1KMT2ANPC1NR2F2 | |
| SCHEMBL4822465 | 0.81 | PDE2A (0.40) | RAB9AMEN1KMT2ANPC1NR2F2 | |
| SCHEMBL4819307 | 0.74 | ALOX5 (0.42) | RAB9AMEN1KMT2ANPC1ADORA3 | |
| SCHEMBL14337403 | 0.72 | MEN1 (0.46) | RAB9AMEN1KMT2ANPC1NR2F2 | |
| SCHEMBL4818794 | 0.72 | ADORA3 (0.43) | RAB9AMEN1KMT2ANPC1ADORA3 | |
| SCHEMBL8805553 | 0.72 | ALDH1A1 (0.47) | RAB9ANPC1ADORA3ADORA2AADORA1 | |
| SCHEMBL8805228 | 0.72 | ALDH1A1 (0.47) | RAB9ANPC1ADORA3ADORA2AADORA1 | |
| SCHEMBL8806220 | 0.70 | ADORA3 (0.42) | MEN1KMT2AADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | claimed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | claimed |
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | disclosed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | TUBB3, TUBA1C, TUBB1 | RAB9A 2541/4885MEN1 2807/4885KMT2A 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.